Atlas Trials

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Clinical trial NCT03660826 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03660826
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaStage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Start date
2018-09-27
Primary completion
2024-12-06
Enrollment
288

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.